- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
similar (log10 iMr Placebo_Baseline=1 98 and log10 iMr TDF_Baselin=1 94,
Wilcoxon Rank-Sum P=0.73). Viral load was significantly
correlated with normalized transcriptionally expressed viral
integrations (Pearson, cor=0 73; p<1x10-10) Notably, after
three years, TDF treated patients (N=62) experienced a
significantly greater reduction in expressed integrations than
patients receiving placebo throughout the trial (Fold Change
BASELINEvsYear3 = -0 49; log10 iMr TDF_Baseline=1 94 and log10 iMr
TDF_Y3=1 45, ANOVA P=0 037) Additionally, patients on TDF
experienced a greater decline in the number of dysregulated
protein coding genes (Wilcoxon rank sum test, P=0 007), many
of which were cancer related (COSMICv91), suggesting these
integrations may have biological importance Conclusion:
Our results suggest that HBV viral suppression with TDF
may reduce viral genomic perturbations and consequently
reduced transcriptional dysregulation of human genes and
genetic pathways caused by viral integrations
Disclosures:
Yao-Chun Hsu – Abbie: Speaking and Teaching; Bristol-Myers Squibb:
Speaking and Teaching; Gilead Sciences: Speaking and Teaching; Gilead
Sciences: Advisory Committee or Review Panel; Gilead Sciences: Grant/
Research Support
Vithika Suri – Gilead Sciences: Employment; Gilead Sciences: Stock
Shareholder
Zhaoshi Jiang – Gilead Sciences: Employment
Diana M Brainard – Gilead: Employment; Gilead: Stock Shareholder
Ondrej Podlaha – Gilead Sciences, Inc : Employment
Anuj Gaggar: sofosbuvir/velpatasvir (Gilead)
The following people have nothing to disclose: Cheng-Hao Tseng
Disclosure information not available at the time of publication: John F Flaherty |
|